stockrow
Saturday 7 November 2026
Export NRIX’s income statement to Excel — free account
Nurix Therapeutics, Inc.
NRIX Healthcare Biotechnology
Nurix Therapeutics, Inc.’s revenue for fiscal 2025 (year ended November 2025) was $84.0 million, up 54.0% from fiscal 2024.
- Revenue
- +8,426.3%
- EPS
- +578.6%
- Free cash flow
- +1,122.1%
Quarter to August 2026, against a year earlier
15.30
0.46
+3.10%
Follow NRIX
Alert me
| Aug '26 | May '26 | Feb '26 | Nov '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
7 | 2 | 2 | 4 |
+8 more TTM periods Free account |
| 43.99% | (80.30%) | (61.40%) | (49.63%) | ||
| 34.33% | (60.57%) | (47.20%) | (38.96%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
29.71% | (84.40%) | (61.02%) | (48.72%) | |
Average Days of Receivables |
10.40 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
3.31 | (2.74) | (2.47) | (3.04) | |
Free Cash Flow |
369.81 | (304.53) | (271.85) | (263.47) | |
Capital Expenditures |
(9.50) | (10.82) | (11.56) | (14.00) | |
| Other line items | |||||
Cash ROIC |
18.34% | (35.99%) | (26.61%) | (23.28%) | |
Accounts Receivable Turnover |
66.22 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
(0.05) | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
47.59% | 927.31% | 461.66% | 377.36% | |
Selling, General and Administrative Expense of Revenue |
11.14% | 155.06% | 77.60% | 62.80% | |
Share Based Compensation of Revenue |
5.79% | 107.84% | 53.84% | 45.21% | |
Operating CF/Net income |
1.29 | 0.86 | 0.88 | 0.94 | |
Depreciation/Fixed assets |
0.29 | 0.35 | 0.38 | 0.38 | |
Capex/Depreciation |
(1.71) | (1.56) | (1.41) | (1.64) | |
Revenue per Share |
6.29 | 0.33 | 0.65 | 0.97 | |
Operating CF per Share |
3.40 | (2.64) | (2.36) | (2.88) | |
Capex per Share |
(0.09) | (0.10) | (0.10) | (0.16) | |
Capex to Sales |
0.01 | 0.29 | 0.16 | 0.17 |
Columns are period end dates · fundamentals updated 2 Nov 2026